Price
*Choose a city for the actual price
The IHC panel for Hodgkin's Lymphoma represents a clinical diagnostic tool that helps medical staff recognize Hodgkin’s lymphoma tumors through lymphatic tissue evaluation. By using particular antibodies the technique helps clinical practitioners identify Hodgkin’s lymphoma cells through protein detection while differentiating them from other pathological lymphomas and reactive lymph node conditions. The IHC panel functions as a vital tool for medical professionals to validate the presence of Reed-Sternberg cells because these cells serve as the diagnostic hallmark of classical Hodgkin’s lymphoma (cHL). Lab experts use protein analysis to determine different lymphoma types so doctors can choose effective treatments.
Doctors use IHC panel for Hodgkin's Lymphoma for patients who have Hodgkin’s lymphoma symptoms such as painless lymph node swellings and night sweats as well as unexplained weight loss, fever and persistent fatigue. These tests are extremely useful for doctors as they can distinguish between the specific problem and other types. Hodgkin’s lymphoma testing will aid in differentiating a case from non-Hodgkin’s lymphoma as well as benign lymphoid hyperplasia. Researchers rely on IHC panels when patients show ambiguous biopsy findings.
An IHC panel for Hodgkin's Lymphoma functions as a series of antibody markers that diagnose Hodgkin’s lymphoma characteristics. The diagnostic markers that are mostly used for Hodgkin’s lymphoma diagnosis include CD30 and CD15 because these proteins are specifically found on Reed-Sternberg cells. Other diagnostic markers PAX5, combined with CD45 and CD20, help medical professionals identify classical Hodgkin’s lymphoma among other potential lymphomas. Some medical facilities conduct EBV-LMP1 (Epstein-Barr virus latent membrane protein 1) testing to determine if Hodgkin’s lymphoma has a viral connection. The combined use of these biomarkers establishes a dependable method of reaching an exact diagnosis.
Lymph node biopsy is the first step of the procedure where a sample of the tissue is collected from one or multiple affected lymph nodes. Special antibodies are used to stain the processed tissue sample so that it can help in the identification of specific proteins that interest the clinical team. Through microscopic evaluation, the pathologist determines the protein expression pattern observed in the stained tissue samples.
The diagnostic tests provide evidence of Hodgkin’s lymphoma and establish its specific subtype. Doctors recommend patients stop using certain medications before the IHC panel for Hodgkin's Lymphoma due to potential bleeding problems during the procedure.